TIGIT and gastric cancer: Other inhibitors or agonists of immune checkpoint molecules, including the inhibitors of CTLA4, LAG3, Tim3, and TIGIT, as well as the agonists of OX40, are currently in clinical trials in the treatment of gastric cancer.